e fif edition of e Lugano Stem Cell Meeting provides a unique opportunity to discuss e above scientific issues wi worldwide leaders in e field wi in a particularly comfortable context. As for e previous editions of e Meeting, e first day will be focused on basic research while e second day will be more specifically devoted to clinical applications and cell erapy trials. 30, 20 · e 20 edition of e Lugano Stem Cell Meeting, under e auspices of e Swiss center of excellence in cardiovascular diseases Cardiocentro Ticino and e Swiss Stem Cell Foundation, offered an update on clinical, translational, and biotechnological advances in regenerative science and medicine pertinent to cardiovascular applications.Cited by: 1. Lugano Stem Cell Meeting. is biennial event was initiated in 2008, and e ird edition planned for e . Regulatory Stem Cell Science e first session provided e opportunity for representa-tives of regulatory agencies in Europe to present e. 15 International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano, Switzerland, 18–22 e, . Stem Cell Update: Highlights from e 20 Lugano Stem Cell Meeting Article (PDF Available) in Journal of Cardiovascular Translational Research 4(2):192-9. ober 20 wi 580 Reads. Managed by a no-profit foundation integrated into e cantonal heal care service, Cardiocentro Ticino is a state-of- e-art, highly specialized university clinic in Cardiology, Cardiac Surgery and Cardioestes esia. 4 Lugano Stem Cell Meeting - Cardiac Regeneration. Cardiocentro Ticino Foundation, Lugano, Switzerland 23 e Palazzo dei Congressi, Lugano. Registration Deadline 15 e . Meetings. iCAST — iCAST research projects for stem cell research and ided to finance a new research institute near e Clinic Hospital in Lugano. e clear vision of e Institute was and is today to develop advanced stem cell erapies for human diseases, rough clinical trials, collaboration wi hospitals and clinics. e Gift of Stem Cells! Since e beginning of our activity as a private cord blood bank - it was 2005, and we were among e very first in Europe - we have defined our procedures in compliance wi e FACT-Netcord standard, also based on e recommendation of . Erratum to: Highlights from e Lugano Stem Cell Meeting By Silvana Bardelli, co Moccetti, Tiziano Tallone, Lucio Barile, Elisabetta Cervio, ina Radrizzani, Lucia Turchetto, Sabrina Soncin, Viviana Lo Cicero, Sara Bolis, Gabriella Andriolo, Daniel Sürder, Giu pe Vassalli, Annarosa Leri, Piero Anversa and Tiziano Moccetti. Here is our listing of Stem Cell Meetings & Conferences. Send me your listings if you don’t see your meeting here. Meeting listings are not endorsements and I try to make is list fairly comprehensive. uary ARM Cell & Gene erapies State of e Industry Briefing San Francisco, CA, USA (Held uary 7, ) World Stem Cell Summit, Miami, FL USA, uary 22-25, . Cellular. e annual one-day meeting of e Swiss Stem Cell Network. In , e conference will be held under e general topic of In ation in Cell erapy. e 20 edition of e Lugano StemCellMeeting, under e auspices of e Swiss center of excellence in cardiovascular diseases Cardiocentro Ticino and e Swiss Stem Cell Foundation, offered an update on clinical, translational, and biotechnological advances in regenerative science and medicine pertinent to cardiovascular applications. Academician Laurentiu M. Popescu, MD, PhD, e discoverer of e telocytes, delivered at e 4 Stem Cell Meeting in Lugano - Switzerland, a lecture on e relationship between telocytes and stem cells. e paper titled 'Telocytes Challenge Cardiac erapy Based on Pure Stem Cells Only' presents data accepted in e scientific world at 'challenge' e dogma of stem cells being e only cell. P4224Superior exosome-mediated paracrine effects of cardiac progenitor cells compared to bone row mesenchymal stem cells derived from e same . TrendTerms displays relevant terms of e abstract of is publication and related documents on a map. e terms and eir relations were extracted from ZORA using word statistics. e 5 Lugano Stem Cell Meeting (LSCM) will take place in Lugano, e most important city in e Italian speaking part of Switzerland. is region is considered one of e most beautiful spots in Europe. VENUE e Symposium will take place at e Univer -. In e educational field, e Cardiocentro Ticino organized two international symposia on stem cell biology and regenerative medicine, e first one on 9– , and e 5 Lugano Stem Cell Meeting on 20–21 e , along wi Meet e Experts (MTE) meeting on interventional cardiology on 21–23 e . Item Type: Journal Article, refereed, original work: Communities & Collections: 04 Faculty of Medicine Cardiocentro Ticino: Dewey imal Classification: 6 Medicine & heal. Search SpringerLink. Search. Highlights from e Lugano Stem Cell Meeting Silvana Bardelli, co Moccetti, Tiziano Tallone, Lucio Barile, Elisabetta Cervio, ina Radrizzani, Lucia Turchetto, Sabrina Soncin, Viviana Lo Cicero, Sara Bolis, Gabriella Andriolo, Daniel Sürder, Giu pe Vassalli, . Lugano criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials Ronald L Van Heertum,1 Robert Scarimbolo,1 John G Wolodzko,1 Barbara Klencke,2 Richard Messmann,3 Feza Tunc,4 Levi Sokol,4 Ra Agarwal,5 James A Strafaci,1 Michael O’Neal1 1Medical Affairs, Bioclinica, Inc., Princeton, NJ, 2Medical Affairs, Sierra Oncology, Brisbane, CA, 3Medical . Allogeneic hematopoietic stem cells transplantation (allo-HSCT) is a potentially curative option for patients wi rrHL. ere are concerns at CPIs before allo- HSCT increase e incidence of graft-versus-host disease, immune-related adverse events, and nonrelapse mortality (NRM). Lucio Barile is group leader of Laboratory for Cardiovascular eranostics at Cardiocentro Ticino Foundation (CCT), Lugano, Switzerland. His research interests are largely direct tods understanding pa ophysiological mechanisms underlying cardiovascular diseases and focuses on finding el cell-free approach to promote successful cardioprotection and myocardial regeneration to prevent. Best poster presentation 4 Lugano Stem Cell Meeting. i . Sprachen. Italian Muttersprache oder zweisprachig. English Verhandlungssicher. German Gute Kenntnisse. French Grundkenntnisse. Gruppen. Life Sciences Switzerland. Life Sciences Switzerland. Title: PhD, Principal Scientist. 16, . CardioCell Scientific Advisory Board Member Presents at e Lugano Stem Cell Meeting. LUGANO, SWITZERLAND – LUGANO STEM CELL MEETING – e 16, – CardioCell LLC, a Stemedica Cell Technologies subsidiary at creates allogeneic stem-cell erapies for cardiovascular indications, announces a presentation by prominent chronic heart failure (HF) opinion . Stem Cell Conferences 2021 2022 is for e researchers, scientists, scholars, engineers, academic, scientific and university practitioners to present research activities at might want to attend events, meetings, seminars, congresses, workshops, summit, and symposiums. 01, · Stem cells will be collected post pri y response assessment. If patients achieve a PR after 3 cycles of Pola+BR and investigator ides to give additional cycles of Pola+BR (up to a max of 6 cycles) en stem cell collection occur between cycles to minimize e chances of collection failure. Erratum to: Highlights from e Lugano Stem Cell Meeting. Journal of Cardiovascular Translational Research, Feb Silvana Bardelli, co Moccetti, Tiziano Tallone, Lucio Barile, Elisabetta Cervio, ina Radrizzani, Lucia Turchetto, Sabrina Soncin, Viviana Lo Cicero, Sara Bolis, et al. Erratum to: Highlights from e Lugano Stem Cell Meeting (J. of Cardiovasc. Trans. Res. 07/s12265-014-9601-5). PTCL included not-o erwise-specified PTCL (PTCL NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large-cell lymphoma (ALCL), and extranodal NK/T-cell lymphoma nasal type (ENKTL). All pts received camrelizumab 200 mg every 2 weeks and apatinib 500 mg once a day wi a cycle of 28 days until e evaluation of disease progression. Cisplatin Chemo erapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12 Lugano, Switzerland, e 19-22, . achieving a response to erapy and meeting criteria for successful stem-cell mobilization. 19, · HBV reactivation is a common complication in patients undergoing B‐cell‐depleting erapy and allogenic hematopoietic stem cell transplantation (allo‐HSCT). Anti‐CD20‐directed monoclonal antibodies cause a rease in e circulating anti‐HBV antibodies, and neutralize antibodies targeting e hepatitis B antigen (HBsAg). MPhil in cardiac stem cell biology John Mores University Liverpool UK (-) FRCS C Fellowship in cardio oracic surgery in UK () CCT in Cardio oracic Surgery Nor West Deanery UK . 01, 2008 · Read Conference calendar, Journal of Gene Medicine on DeepDyve, e largest online rental service for scholarly research wi ousands of academic publications available at your fingertips. Stem cell activity of ese Nes-GFP + cells is suggested by e fact at is fraction contains all e CFU-F activity in e bone row and is able to form clonal spheres at can self-renew, multi-differentiate at e clonal level into e major mesenchymal lineages, and generate hematopoietic activity in vivo upon serial transplantation. Contact: [email protected] Twitter: We are located at e Department of Biomedicine (DBM), University Hospital, in Basel, Switzerland. e combination of ibrutinib and nivolumab had an acceptable safety profile and preliminary activity was similar to at reported wi single-agent ibrutinib in chronic lymphocytic leukaemia or small lymphocytic lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma. e clinical response in patients wi Richter's transformation was promising and supports fur er clinical assessment. Stem Cell Research- could be an outstanding event at brings along a el and International mixture of researchers, dors, leading universities and stem cell analysis establishments creating e conference an ideal platform to share knowledge, adoptive collaborations across trade and world, and assess rising technologies across e world. Box. Cutaneous epi elial stem cells and eir niche. Cutaneous epi elial stem cells maintain e epi elium of e skin and its appendages, as has been reviewed extensively elsewhere (e.g. Hsu et al., ). e skin broadly consists of an interfollicular epidermis, which is a stratified, keratinising squamous epi elium, which forms a protective barrier to e outside world, and its. 28, · Introduction. Patients wi Hodgkin lymphoma (HL) who relapse after autologous hematopoietic cell transplantation (auto-HCT) have a poor prognosis and very limited options, wi a median overall survival (OS) of 2.4 years. 1 Reduced-intensity (RIC) allogeneic hematopoietic cell transplantation (allo-HCT) is a curative option for some patients, wi a 1-year progression-free . 15, · Long-term analyses of e EBMT survey provided evidence at e instrument can foresee trends wi high predictability and very rapidly (e.g., e increasing use of cord blood as a stem cell source, e change from bone row to peripheral blood or e utilization and integration of unrelated donor transplants 4,5) and can us provide. : Lugano Stem Cell Meeting, Switzerland. : e Company of Biologists workshop on Transdifferentiation and Tissue Plasticity in Cardiovascular Rejuvenation , Whiston House, Steining, West Sus, UK. : National Congress of e Italian Society of Pharmacology, Naples. Apr 06, · a Phase II Polish study presented in Lugano looked at RIT consolidation in 46 patients wi mantle-cell lymphoma (MCL) ineligible for autologous stem cell transplantation or after chemosensitive relapse and reported an encouraging median PFS of 3.5 years. ano er paper from EHa documented excellent outcomes in 39. 30, · TAK-981 TBD, infusion, intravenously, once on Days 1 and 8 of each 21-day treatment cycle in combination wi rituximab 375 mg/m^2, infusion, intravenously, once on Days 1, 8, and 15 of Cycle 1 and en on Day 1 of each 21-day treatment cycle from Cycle 2 for up to PD or unacceptable toxicity in participants wi r/r diffuse large B-cell lymphoma (DLBCL) progressed or relapsed after a . 27, · Schuster S, et al. Pri y Analysis of iet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients wi Relapsed or Refractory Diffuse Large B-Cell Lymphoma. 59 American Society of Hematology Annual Meeting and Exposition. Abstract 577. Atlanta, GA. ember 9-12, . BackgroundMantle cell lymphoma (MCL) is a clinically and pa ogenetically distinct B-cell non-Hodgkin lymphoma at presents at a median age of 65 years and typ.